Multimodal Electrophysiological Study of Cortico-subcortical Biomarkers of Tics in Tourette Syndrome
Launched by UNIVERSITY HOSPITAL, BORDEAUX · Apr 1, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying Tourette Syndrome (TS), a condition that causes involuntary movements and sounds, often starting in childhood. Researchers want to better understand the brain activity associated with tics and identify specific markers that can help predict when tics will occur. The goal is to improve treatments, especially for patients who have not found relief with standard therapies. The study will involve 10 patients aged 16 and older who have severe TS that has not responded to medications, and who are receiving a specific type of treatment called deep brain stimulation.
Participants in the trial will have their brain activity monitored after their surgery, using advanced technology that captures brain signals. They will also perform voluntary movements to help distinguish between normal actions and tics. This research is important because it could lead to new treatment methods that adapt to a person's brain signals, potentially reducing unwanted side effects and improving overall effectiveness. If you or someone you know has severe TS and is interested in participating, it’s essential to meet certain criteria, including being at least 16 years old and having a normal brain MRI.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient at least 16 years old.
- • Disabling and drug-resistant Tourette's syndrome.
- • Receiving deep brain stimulation treatment with implantation of the PERCEPT™ Device as part of their medical management.
- • Normal brain MRI.
- • Subject affiliated or beneficiary of a social security system.
- • Free and informed consent of the patient and, for minors, of the minor and at least one parental authority.
- Exclusion Criteria:
- • Major depressive syndrome (Beck Depression Inventory (BDI-II) \> 20).
- • MRI showing significant brain atrophy or significant hyperintensities.
- • Pregnant or nursing mothers.
- • Person unable to give personal consent.
- • Person subject to a legal protection measure (curatorship, guardianship) or placed under court protection.
- • Patient included in another research protocol with an interdiction of participation to another research or in an exclusion period
About University Hospital, Bordeaux
The University Hospital of Bordeaux is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution integrates cutting-edge scientific inquiry with patient care, fostering an environment that encourages collaboration among multidisciplinary teams. With a commitment to improving treatment outcomes and enhancing patient safety, the University Hospital of Bordeaux plays a pivotal role in the development of new therapies and medical technologies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux, , France
Patients applied
Trial Officials
Edouard COURTIN, Dr
Principal Investigator
University Hospital, Bordeaux
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported